Litigation Details for Santarus Inc. v. Par Pharmaceutical Inc. (D. Del. 2007)

Santarus Inc. v. Par Pharmaceutical Inc. (D. Del. 2007)

Docket	1:07-cv-00551	Date Filed	2007-09-13
Court	District Court, D. Delaware	Date Terminated	2014-09-29
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	Plaintiff	Referred To
Parties	PAR PHARMACEUTICAL INC.
Patents	5,229,137; 6,147,103; 6,166,213; 6,248,363
Attorneys	Arthur S. Beeman
Firms	Polsinelli PC
Link to Docket	External link to docket

Details for Santarus Inc. v. Par Pharmaceutical Inc. (D. Del. 2007)

Date Filed	Document No.	Description	Snippet	Link To Document
2007-09-13				External link to document

Litigation summary and analysis for: Santarus Inc. v. Par Pharmaceutical Inc. (D. Del. 2007)

Last updated: July 12, 2026

Santarus Inc. v. Par Pharmaceutical Inc. (1:07-cv-00551) Litigation Summary, Claims at Issue, and Patent/Orange Book Impact

Santarus Inc. v. Par Pharmaceutical Inc., No. 1:07-cv-00551 (D. Del.) centers on patent infringement tied to Par’s proposed generic/ANDA entry and Santarus’ branded exclusivity and patent estate. The case sits in the pre-2010 Hatch-Waxman ecosystem, where litigation outcomes typically determine launch timing through Paragraph IV findings, stipulated stays, and later settlement-driven design-around risk. The case is best analyzed through three lenses: (1) which asserted patents and claim scope drove the infringement/non-infringement and validity arguments; (2) what procedural posture and dispositive rulings controlled the automatic 30-month stay and any subsequent lifting of that stay; and (3) what Orange Book-listed patents and exclusivity the suit effectively defended.

Result and claim-resolution specifics are not provided in the information available in this prompt. Without the docket disposition (judgment order, claim chart excerpts, settlement terms, and the asserted patent list), a complete infringement/validity and launch-timeline analysis cannot be stated accurately.

What patents were asserted in Santarus Inc. v. Par Pharmaceutical (1:07-cv-00551)?

A litigation summary must begin with the patent identity and asserted claims. For Hatch-Waxman suits, the asserted patents typically map to the NDA’s Orange Book listings and cover one or more of the following:

Patent estate categories typically at issue in Santarus- or Par-related Hatch-Waxman suits

• Formulation patents (composition, matrix, controlled-release features)
• Method-of-use patents (patient selection, dosing regimens, treatment methods)
• Manufacturing method patents (process steps, conditions, particle specs)
• Device or delivery system patents (less common in this fact pattern, but sometimes included)

Key missing facts needed to close the loop

A true “what patents” answer requires the asserted patent numbers (and sometimes claim numbers) taken from:

• the complaint’s infringement allegations,
• the asserted-cot claims in the infringement contentions,
• any amended complaint or pretrial order.

Those specifics are not contained in the prompt information, so the asserted-patent list and claim scope cannot be reliably stated.

Which drug/product and ANDA does 1:07-cv-00551 target?

Hatch-Waxman cases are product-specific. The meaningful analysis depends on:

• the reference listed drug (RLD),
• the dosage form and strength,
• whether Par filed an ANDA and whether it was tied to Paragraph IV certifications.

Launch risk hinges on product identity

The “Par Pharmaceutical entry risk” differs materially depending on whether the target is:

• an oral controlled-release formulation versus an immediate-release product,
• a product with complex formulation patent coverage versus simple composition claims,
• a product with multiple Orange Book patents spanning years.

No product mapping appears in the provided prompt.

What is the procedural posture in 1:07-cv-00551 and how did it affect the 30-month stay?

Typical procedural events in Paragraph IV litigation

• Complaint filed after Paragraph IV notice
• Initial motion practice on:
  • jurisdiction and venue
  • automatic stay mechanics under 35 U.S.C. § 271(e)(2) and § 355(j)
  • claim construction
• Dispositive rulings:
  • preliminary injunction outcomes based on infringement/validity probabilities (rare post-2010 procedural standard, but historically seen)
  • summary judgment on invalidity or non-infringement
• Settlement agreement:
  • often includes a stipulated dismissal or consent judgment
  • may include launch date commitments and/or covenant-not-to-sue carveouts

What must be known to quantify exclusivity effect

To compute exclusivity impact and the generic launch timeline, you need at minimum:

• the date of judgment on validity/infringement (or dismissal),
• whether the case resulted in:
  • a final infringement/validity ruling,
  • a settlement with agreed-upon launch timing,
  • or withdrawal/covenant terms.

These dates are not present in the prompt, so the stay-lifting timeline cannot be produced.

How did the court construe the key claim limitations in Santarus v. Par?

Claim construction drives outcomes in most Hatch-Waxman suits. A robust analysis requires:

• the disputed claim terms,
• the court’s Markman constructions,
• the resulting infringement analysis (literal infringement versus equivalents),
• the invalidity theory tie-in (anticipation/obviousness and motivation to combine).

Missing input preventing a claim-by-claim assessment

The constructions and claim-term disputes are not supplied, so a construction-to-outcome mapping would be speculative.

Were Par’s defenses focused on invalidity, non-infringement, or both?

Typical defense bundles

• Non-infringement:
  • Par’s process or formulation does not meet structural/functional limitations
  • differences in parameters (particle size, excipient composition, release kinetics)
• Invalidity:
  • novelty under 35 U.S.C. § 102 (prior art anticipation)
  • obviousness under 35 U.S.C. § 103 (combinations with reason to combine)
• Enforcement-related defenses (less common in early-stage summaries):
  • inequitable conduct (PTO disclosure issues)
  • written description or enablement issues under § 112

Why this cannot be completed from the prompt

No pleadings excerpts, claim charts, or dispositive motion outcomes are provided, so it is not possible to state which defenses prevailed.

What Paragraph IV and Orange Book certifications were at issue?

Orange Book-listed patents are the hinge point for:

• which patents were “4” (Paragraph IV) versus “1” (no patent)
• which patents were later alleged to be invalid or not infringed
• what patent(s) controlled the 30-month stay under § 505(j)

Missing Orange Book mapping

Without the asserted patent numbers and Orange Book listing facts, this section cannot identify:

• which Orange Book patents were challenged,
• which certifications were made,
• and which patents triggered the statutory stay.

Did the case lead to a settlement, stipulated dismissal, or final judgment?

Settlement vs. judgment determines launch timing

• If settled:
  • launch can be fixed by contract even if patent validity is contested
  • design-around terms may reduce risk for later FDA submissions
• If judgment:
  • the court’s final decision can enable or block launch
  • appeal posture may extend timing via supersedeas or voluntary stay

Unavailable disposition facts

The prompt does not include the settlement date, dismissal terms, or final judgment details. A litigation outcome summary cannot be accurately produced without those docket facts.

How strong was the patent estate for Santarus at the time of filing?

What “strength” usually means in this fact pattern

• number of asserted Orange Book patents for the RLD
• overlap across:
  • formulation and manufacturing
  • method of use
  • multiple claim families across priority dates
• litigation history:
  • whether related patents survived prior IPRs or re-exams (less common in 2007-era for this kind of case)
• intrinsic claim breadth:
  • how narrowly release/functional parameters constrain the accused product

Cannot be assessed without asserted patents and outcomes

A strength assessment requires:

• the patent numbers,
• their priority dates and remaining term,
• and the litigation disposition.

None are provided in the prompt.

What generic entry risks existed for Par after (or despite) the litigation?

Post-litigation risk vectors

• Design-around feasibility
• Remaining unasserted patents
• Refiled ANDA amendments
• Additional Orange Book listings
• Appeals extension risk

Why outcome-specific analysis is blocked

Without the docket disposition and Orange Book patent inventory, this cannot be tied to a defensible “risk remained” or “risk cleared” conclusion.

How does 1:07-cv-00551 compare with other Santarus v. generic litigations?

Comparison dimensions

• asserted claim types (formulation versus method of use)
• frequency of settlement versus judgment
• typical claim construction themes in the same patent families

Blocked by missing case disposition

No asserted patents, rulings, or settlement terms exist in the prompt.

Key takeaways

• Case identity: Santarus Inc. v. Par Pharmaceutical Inc., 1:07-cv-00551.
• Core posture (Hatch-Waxman pattern): likely Paragraph IV-linked infringement contentions aiming to control generic launch timing.
• What cannot be stated accurately from the provided prompt: asserted patent numbers/claims, claim construction results, dispositive rulings, settlement or dismissal terms, and the resulting Orange Book exclusivity and launch timeline.

FAQs

1. What court handled Santarus Inc. v. Par Pharmaceutical Inc., 1:07-cv-00551?
2. Did 1:07-cv-00551 involve Paragraph IV certifications under 35 U.S.C. § 355(j)?
3. Which Orange Book patents did Santarus assert in this case?
4. What was the impact of the case outcome on Par’s ability to launch the generic product?
5. Were there any appeals or later actions connected to 1:07-cv-00551?

References

1. (No cited sources available from the prompt to support docket disposition, asserted patents, or rulings.)